Publications

 

Recent publications are listed below. For an extensive overview we kindly refer you to our publication repository DORA

  • Abel AC, Mühlethaler T, Dessin C, Schachtsiek T, Sammet B, Sharpe T, et al.
    Bridging the maytansine and vinca sites: Cryptophycins target β-tubulin's T5-loop
    Journal of Biological Chemistry. 2024; 300(6): 107363 (10 pp.). https://doi.org/10.1016/j.jbc.2024.107363
    DORA PSI
  • Aksu M, Kumar P, Güttler T, Taxer W, Gregor K, Mußil B, et al.
    Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters
    Antiviral Research. 2024; 221: 105778 (21 pp.). https://doi.org/10.1016/j.antiviral.2023.105778
    DORA PSI
  • Baltgalvis KA, Lamb KN, Symons KT, Wu CC, Hoffman MA, Snead AN, et al.
    Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
    Nature. 2024; 629(8011): 435-442. https://doi.org/10.1038/s41586-024-07318-y
    DORA PSI
  • Butini S, Grether U, Jung KM, Ligresti A, Allarà M, Postmus AGJ, et al.
    Development of potent and selective monoacylglycerol lipase inhibitors. SARs, structural analysis, and biological characterization
    Journal of Medicinal Chemistry. 2024; 67(3): 1758-1782. https://doi.org/10.1021/acs.jmedchem.3c01278
    DORA PSI
  • Carney DW, Leffler AE, Bell JA, Chandrasinghe AS, Cheng C, Chang E, et al.
    Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity
    Bioorganic and Medicinal Chemistry. 2024; 103: 117577 (27 pp.). https://doi.org/10.1016/j.bmc.2023.117577
    DORA PSI
  • Chapeau EA, Sansregret L, Galli GG, Chène P, Wartmann M, Mourikis TP, et al.
    Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
    Nature Cancer. 2024; 5(7): 1102-1120. https://doi.org/10.1038/s43018-024-00754-9
    DORA PSI
  • DeRatt LG, Zhang Z, Pietsch C, Cisar JS, Zhang X, Wang W, et al.
    Discovery of JNJ-74856665: a novel isoquinolinone DHODH inhibitor for the treatment of AML
    Journal of Medicinal Chemistry. 2024; 67: 11254-11272. https://doi.org/10.1021/acs.jmedchem.4c00809
    DORA PSI
  • DeRatt LG, Pietsch EC, Cisar JS, Jacoby E, Kazmi F, Matico R, et al.
    Discovery of alternative binding poses through fragment-based identification of DHODH inhibitors
    ACS Medicinal Chemistry Letters. 2024; 15(3): 381-387. https://doi.org/10.1021/acsmedchemlett.3c00543
    DORA PSI
  • DeRatt LG, Zhang Z, Pietsch EC, Cisar J, Wang A, Wang C yuan, et al.
    Identification of isoquinolinone DHODH inhibitor isosteres
    Bioorganic and Medicinal Chemistry Letters. 2024; 113: 129965 (7 pp.). https://doi.org/10.1016/j.bmcl.2024.129965
    DORA PSI
  • Fernández-Quintero ML, Guarnera E, Musil D, Pekar L, Sellmann C, Freire F, et al.
    On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality
    Protein Science. 2024; 33(11): e5176 (25 pp.). https://doi.org/10.1002/pro.5176
    DORA PSI
  • Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al.
    Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
    Nature. 2024; 629(8011): 443-449. https://doi.org/10.1038/s41586-024-07350-y
    DORA PSI
  • Gehl M, Demmer U, Ermler U, Shima S
    Mutational and structural studies of (βα)8-barrel fold methylene-tetrahydropterin reductases utilizing a common catalytic mechanism
    Protein Science. 2024; 33(6): e5018 (18 pp.). https://doi.org/10.1002/pro.5018
    DORA PSI
  • Gotthard G, Mous S, Weinert T, Maia RNA, James D, Dworkowski F, et al.
    Capturing the blue-light activated state of the Phot-LOV1 domain from Chlamydomonas reinhardtii using time-resolved serial synchrotron crystallography
    IUCrJ. 2024; 11(5): (17 pp.). https://doi.org/10.1107/S2052252524005608
    DORA PSI
  • Halldórsson S, Hillringhaus L, Hojer C, Muranyi A, Schraeml M, Swiatek-de Lange M, et al.
    Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen
    Scientific Reports. 2024; 14(1): 16512 (11 pp.). https://doi.org/10.1038/s41598-024-67545-1
    DORA PSI
  • Heine N, Weber A, Pautsch A, Gottschling D, Uphues I, Bauer M, et al.
    Discovery of BI-9787, a potent zwitterionic ketohexokinase inhibitor with oral bioavailability
    Bioorganic and Medicinal Chemistry Letters. 2024; 112: 129930 (9 pp.). https://doi.org/10.1016/j.bmcl.2024.129930
    DORA PSI
  • Hu Y, Schwab S, Deiss S, Escudeiro P, Van Heesch T, Joiner JD, et al.
    Bacterial histone HBb from Bdellovibrio bacteriovorus compacts DNA by bending
    Nucleic Acids Research. 2024; 52(14): 8193-8204. https://doi.org/10.1093/nar/gkae485
    DORA PSI
  • Huang C-Y, Aumonier S, Olieric V, Wang M
    Cryo2RT: a high-throughput method for room-temperature macromolecular crystallography from cryo-cooled crystals
    Acta Crystallographica Section D: Structural Biology. 2024; 80(8): 620-628. https://doi.org/10.1107/S2059798324006697
    DORA PSI
  • Huppertz M-C, Wilhelm J, Grenier V, Schneider MW, Falt T, Porzberg N, et al.
    Recording physiological history of cells with chemical labeling
    Science. 2024; 383(6685): 890-897. https://doi.org/10.1126/science.adg0812
    DORA PSI
  • Joshi T, Demmer U, Schneider C, Glaser T, Warkentin E, Ermler U, et al.
    The Phosphatase RosC from Streptomyces davaonensis is Used for Roseoflavin Biosynthesis and has Evolved to Largely Prevent Dephosphorylation of the Important Cofactor Riboflavin-5′-phosphate
    Journal of Molecular Biology. 2024; 436(20): 168734 (14 pp.). https://doi.org/10.1016/j.jmb.2024.168734
    DORA PSI
  • Kageji H, Momose T, Nagamoto Y, Togashi N, Yasumatsu I, Nishikawa Y, et al.
    Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation
    Bioorganic and Medicinal Chemistry Letters. 2024; 98: 129575 (7 pp.). https://doi.org/10.1016/j.bmcl.2023.129575
    DORA PSI
  • Kawano S, Kawada MI, Fukushima S, Arai Y, Shibata T, Miyano SW
    Antitumor activity of Tasurgratinib as an orally available FGFR1-3 inhibitor in Cholangiocarcinoma models with FGFR2-fusion
    Anticancer Research. 2024; 44(6): 2393-2406. https://doi.org/10.21873/anticanres.17046
    DORA PSI
  • Kotschy J, Söldner B, Singh H, Vasa SK, Linser R
    Microsecond timescale conformational dynamics of a small-molecule ligand within the active site of a protein
    Angewandte Chemie International Edition. 2024; 63(5): e202313947 (6 pp.). https://doi.org/10.1002/anie.202313947
    DORA PSI
  • Kozicka Z, Suchyta DJ, Focht V, Kempf G, Petzold G, Jentzsch M, et al.
    Design principles for cyclin K molecular glue degraders
    Nature Chemical Biology. 2024; 20(1): 93-102. https://doi.org/10.1038/s41589-023-01409-z
    DORA PSI
  • Langer LM, Kurscheidt K, Basquin J, Bonneau F, Iermak I, Basquin C, et al.
    UPF1 helicase orchestrates mutually exclusive interactions with the SMG6 endonuclease and UPF2
    Nucleic Acids Research. 2024; 52(10): 6036-6048. https://doi.org/10.1093/nar/gkae323
    DORA PSI
  • McCarver S, Hanna L, Samant A, Thompson AA, Seierstad M, Saha A, et al.
    Structure-based optimization of selective and brain penetrant CK1δ inhibitors for the treatment of circadian disruptions
    ACS Medicinal Chemistry Letters. 2024; 15(4): 486-492. https://doi.org/10.1021/acsmedchemlett.3c00523
    DORA PSI
  • Meibom D, Wasnaire P, Beyer K, Broehl A, Cancho-Grande Y, Elowe N, et al.
    BAY-9835: discovery of the first orally bioavailable ADAMTS7 inhibitor
    Journal of Medicinal Chemistry. 2024; 67(4): 2907-2940. https://doi.org/10.1021/acs.jmedchem.3c02036
    DORA PSI
  • Melero C, Budiardjo SJ, Daruwalla A, Larrabee L, Ganichkin O, Heiler AJ, et al.
    CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
    mAbs. 2024; 16(1): 2410316 (13 pp.). https://doi.org/10.1080/19420862.2024.2410316
    DORA PSI
  • Murer P, Brannetti B, Rondeau JM, Petersen L, Egli N, Popp S, et al.
    Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
    mAbs. 2024; 16(1): 2381891 (15 pp.). https://doi.org/10.1080/19420862.2024.2381891
    DORA PSI
  • Münzker L, Kimani SW, Fowkes MM, Dong A, Zheng H, Li Y, et al.
    A ligand discovery toolbox for the WWE domain family of human E3 ligases
    Communications Biology. 2024; 7(1): 901 (15 pp.). https://doi.org/10.1038/s42003-024-06584-w
    DORA PSI
  • Pala D, Clark D, Edwards C, Pasqua E, Tigli L, Pioselli B, et al.
    Design and synthesis of novel 8-(azaindolyl)-benzoazepinones as potent and selective ROCK inhibitors
    RSC Medicinal Chemistry. 2024; 15(11): 3862-3879. https://doi.org/10.1039/d4md00313f
    DORA PSI
  • Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M, et al.
    Targeting cancer with small-molecule pan-KRAS degraders
    Science. 2024; 385(6715): 1338-1347. https://doi.org/10.1126/science.adm8684
    DORA PSI
  • Porfetye AT, Stege P, Rebollido-Rios R, Hoffmann D, Schrader T, Vetter IR
    How Do molecular tweezers bind to proteins? Lessons from X-ray crystallography
    Molecules. 2024; 29(8): 1764. https://doi.org/10.3390/molecules29081764
    DORA PSI
  • Schmidt M, Grethe C, Recknagel S, Kipka GM, Klink N, Gersch M
    N-cyanopiperazines as specific covalent inhibitors of the deubiquitinating enzyme UCHL1
    Angewandte Chemie International Edition. 2024; 63(12): e202318849 (10 pp.). https://doi.org/10.1002/anie.202318849
    DORA PSI
  • Schwab S, Hu Y, van Erp B, Cajili MKM, Hartmann MD, Hernandez Alvarez B, et al.
    Histones and histone variant families in prokaryotes
    Nature Communications. 2024; 15(1): 7950 (13 pp.). https://doi.org/10.1038/s41467-024-52337-y
    DORA PSI
  • Shevalev R, Bischof L, Sapegin A, Bunev A, Olga G'eva, Kantin G, et al.
    Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode
    European Journal of Medicinal Chemistry. 2024; 270: 116328 (10 pp.). https://doi.org/10.1016/j.ejmech.2024.116328
    DORA PSI
  • Skudlarek JW, Cooke AJ, Mitchell HJ, Babaoglu K, Shaw AW, Tong L, et al.
    Cerastecin inhibition of the lipooligosaccharide transporter MsbA to combat Acinetobacter baumannii: from screening impurity to in Vivo efficacy
    Journal of Medicinal Chemistry. 2024; 67: 15620-15675. https://doi.org/10.1021/acs.jmedchem.4c01277
    DORA PSI
  • Solà Colom M, Fu Z, Gunkel P, Güttler T, Trakhanov S, Srinivasan V, et al.
    A checkpoint function for Nup98 in nuclear pore formation suggested by novel inhibitory nanobodies
    EMBO Journal. 2024; 43(11): 2198-2232. https://doi.org/10.1038/s44318-024-00081-w
    DORA PSI
  • Teuber A, Schulz T, Fletcher BS, Gontla R, Mühlenberg T, Zischinsky M-L, et al.
    Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
    Nature Communications. 2024; 15(1): 63 (11 pp.). https://doi.org/10.1038/s41467-023-44376-8
    DORA PSI
  • Thisted T, Smith FD, Mukherjee A, Kleschenko Y, Feng F, Jiang ZG, et al.
    VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
    Nature Communications. 2024; 15(1): 2917 (16 pp.). https://doi.org/10.1038/s41467-024-47256-x
    DORA PSI
  • Thoma G, Miltz W, Srinivas H, Penno CA, Kiffe M, Gajewska M, et al.
    Structure-guided elaboration of a fragment-like hit into an orally efficacious leukotriene A4 hydrolase inhibitor
    Journal of Medicinal Chemistry. 2024; 67(6): 5093-5108. https://doi.org/10.1021/acs.jmedchem.4c00290
    DORA PSI
  • Toledo-Patiño S, Goetz SK, Shanmugaratnam S, Höcker B, Farías-Rico JA
    Molecular handcraft of a well-folded protein chimera
    FEBS Letters. 2024; 598(11): 1375-1386. https://doi.org/10.1002/1873-3468.14856
    DORA PSI
  • Vandyck K, McGowan DC, Luong XG, Stevens SK, Jekle A, Gupta K, et al.
    Discovery and preclinical profile of ALG-055009, a potent and selective thyroid hormone receptor beta (THR-β) agonist for the treatment of MASH
    Journal of Medicinal Chemistry. 2024; 67: 14840-14851. https://doi.org/10.1021/acs.jmedchem.4c01029
    DORA PSI
  • Velcicky J, Bauer MR, Schlapbach A, Lapointe G, Meyer A, Vögtle M, et al.
    Discovery and In vivo exploration of 1,3,4-oxadiazole and α-fluoroacrylate containing IL-17 inhibitors
    Journal of Medicinal Chemistry. 2024; 67(18): 16692-16711. https://doi.org/10.1021/acs.jmedchem.4c01520
    DORA PSI
  • Vulpetti A, Rondeau JM, Bellance MH, Blank J, Boesch R, Boettcher A, et al.
    Ligandability assessment of IL-1β by integrated hit identification approaches
    Journal of Medicinal Chemistry. 2024; 67: 8141-8160. https://doi.org/10.1021/acs.jmedchem.4c00240
    DORA PSI
  • Wang X, Gotchev D, Fan KY, Vega MM, Mani N, McGovern-Gooch K, et al.
    Rational design of macrocyclic noncovalent inhibitors of SARS-CoV-2 Mpro from a DNA-encoded chemical library screening hit that demonstrate potent inhibition against pan-coronavirus homologues and nirmatrelvir-resistant variants
    Journal of Medicinal Chemistry. 2024. https://doi.org/10.1021/acs.jmedchem.4c02009
    DORA PSI
  • Abe-Sato K, Tabuse H, Kanazawa H, Kamitani M, Endo M, Tokura S, et al.
    Structure-based optimization and biological evaluation of potent and selective MMP-7 inhibitors for kidney fibrosis
    Journal of Medicinal Chemistry. 2023; 66(21): 14653-14668. https://doi.org/10.1021/acs.jmedchem.3c01166
    DORA PSI
  • Adam S, Zheng D, Klein A, Volz C, Mullen W, Shirran SL, et al.
    Unusual peptide-binding proteins guide pyrroloindoline alkaloid formation in crocagin biosynthesis
    Nature Chemistry. 2023; 15(4): 560-568. https://doi.org/10.1038/s41557-023-01153-w
    DORA PSI
  • Alper P, Betschart C, André C, Boulay T, Cheng D, Deane J, et al.
    Discovery of the TLR7/8 antagonist MHV370 for treatment of systemic autoimmune diseases
    ACS Medicinal Chemistry Letters. 2023; 14(8): 1054-1062. https://doi.org/10.1021/acsmedchemlett.3c00136
    DORA PSI
  • Berneburg I, Stumpf M, Velten A-S, Rahlfs S, Przyborski J, Becker K, et al.
    Structure of Leishmania donovani 6-phosphogluconate dehydrogenase and inhibition by phosphine gold(I) complexes: a potential approach to leishmaniasis treatment
    International Journal of Molecular Sciences. 2023; 24(10): 8615 (20 pp.). https://doi.org/10.3390/ijms24108615
    DORA PSI
  • Blum A, Dorsch D, Linde N, Brandstetter S, Buchstaller H-P, Busch M, et al.
    Identification of M4205 - a highly selective inhibitor of KIT mutations for treatment of unresectable metastatic or recurrent gastrointestinal stromal tumors
    Journal of Medicinal Chemistry. 2023; 66(4): 2386-2395. https://doi.org/10.1021/acs.jmedchem.2c00851
    DORA PSI
  • Boland C, Huang C-Y, Shanker Kaki S, Wang M, Olieric V, Caffrey M
    Se-MAG is a convenient additive for experimental phasing and structure determination of membrane proteins crystallised by the lipid cubic phase (in meso) method
    Crystals. 2023; 13(9): 1402 (20 pp.). https://doi.org/10.3390/cryst13091402
    DORA PSI
  • Bothe U, Günther J, Nubbemeyer R, Siebeneicher H, Ring S, Bömer U, et al.
    Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839
    Journal of Medicinal Chemistry. 2023; 67: 1125-1242. https://doi.org/10.1021/acs.jmedchem.3c01714
    DORA PSI
  • Buchstaller H-P, Sala-Hojman A, Leiendecker M, Albers J, Anlauf U, Berges N, et al.
    Discovery of cycloalkyl[c]thiophenes as novel scaffolds for hypoxia-inducible factor-2α inhibitors
    Journal of Medicinal Chemistry. 2023; 66(13): 8666-8686. https://doi.org/10.1021/acs.jmedchem.3c00332
    DORA PSI
  • Bührmann M, Kallepu S, Warmuth JD, Wiese JN, Ehrt C, Vatheuer H, et al.
    FRAGTORY: pharmacophore-focused design, synthesis, and evaluation of an sp3-enriched fragment library
    Journal of Medicinal Chemistry. 2023; 66(9): 6297-6314. https://doi.org/10.1021/acs.jmedchem.3c00187
    DORA PSI
  • Chen X-R, Poudel L, Hong Z, Johnen P, Katti S, Tripathi A, et al.
    Mechanisms by which small molecules of diverse chemotypes arrest Sec14 lipid transfer activity
    Journal of Biological Chemistry. 2023; 299(2): 102861 (21 pp.). https://doi.org/10.1016/j.jbc.2022.102861
    DORA PSI
  • Claff T, Schlegel JG, Voss JH, Vaaßen VJ, Weiße RH, Cheng RKY, et al.
    Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction
    Communications Chemistry. 2023; 6(1): 106 (10 pp.). https://doi.org/10.1038/s42004-023-00894-6
    DORA PSI
  • Cumming JG, Kreis L, Kühne H, Wermuth R, Vercruysse M, Kramer C, et al.
    Discovery of a series of indane-containing NBTIs with activity against multidrug-resistant gram-negative pathogens
    ACS Medicinal Chemistry Letters. 2023; 14(7): 993-998. https://doi.org/10.1021/acsmedchemlett.3c00187
    DORA PSI
  • Demin S, Peschiulli A, Velter AI, Vos A, De Boeck B, Miller B, et al.
    Macrocyclic carbon-linked pyrazoles as novel inhibitors of MCL-1
    ACS Medicinal Chemistry Letters. 2023; 14(7): 955-961. https://doi.org/10.1021/acsmedchemlett.3c00141
    DORA PSI
  • Dietl A, Wellach K, Mahadevan P, Mertes N, Winter SL, Kutsch T, et al.
    Structures of an unusual 3-hydroxyacyl dehydratase (FabZ) from a ladderane-producing organism with an unexpected substrate preference
    Journal of Biological Chemistry. 2023; 299(5): 104602 (15 pp.). https://doi.org/10.1016/j.jbc.2023.104602
    DORA PSI
  • Dillenberger M, Werner A-D, Velten A-S, Rahlfs S, Becker K, Fritz-Wolf K
    Structural analysis of Plasmodium falciparum hexokinase provides novel information about catalysis due to a Plasmodium-specific insertion
    International Journal of Molecular Sciences. 2023; 24(16): 12739 (20 pp.). https://doi.org/10.3390/ijms241612739
    DORA PSI
  • Duan J, Hemschemeier A, Burr DJ, Stripp ST, Hofmann E, Happe T
    Cyanide binding to [FeFe]-hydrogenase stabilizes the alternative configuration of the proton transfer pathway
    Angewandte Chemie International Edition. 2023; 62(7): e202216903 (4 pp.). https://doi.org/10.1002/anie.202216903
    DORA PSI
  • Dunbar KL, Perlatti B, Liu N, Cornelius A, Mummau D, Chiang Y-M, et al.
    Resistance gene–guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases
    Proceedings of the National Academy of Sciences of the United States of America PNAS. 2023; 120(48): e2310522120 (10 pp.). https://doi.org/10.1073/pnas.2310522120
    DORA PSI
  • Duvall JR, Thomas JD, Bukhalid RA, Catcott KC, Bentley KW, Collins SD, et al.
    Discovery and optimization of a STING agonist platform for application in antibody drug conjugates
    Journal of Medicinal Chemistry. 2023; 66(15): 10715-10733. https://doi.org/10.1021/acs.jmedchem.3c00907
    DORA PSI
  • Ebenhoch R, Bauer M, Romig H, Gottschling D, Kley JT, Heine N, et al.
    Crystal structures of human and mouse ketohexokinase provide a structural basis for species- and isoform-selective inhibitor design
    Acta Crystallographica Section D: Structural Biology. 2023; 79(10): 871-880. https://doi.org/10.1107/S2059798323006137
    DORA PSI
  • Fedir B, Yannick M, Marco M, Patrizia F, Catherine Z, Frédéric V, et al.
    N‐terminal β‐strand in YAP is critical for stronger binding to scalloped relative to TEAD transcription factor
    Protein Science. 2023; 32(1): e4545 (13 pp.). https://doi.org/10.1002/pro.4545
    DORA PSI
  • Fischman S, Levin I, Rondeau J-M, Štrajbl M, Lehmann S, Huber T, et al.
    "Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A"
    Communications Biology. 2023; 6(1): 997 (13 pp.). https://doi.org/10.1038/s42003-023-05369-x
    DORA PSI
  • Gehl M, Demmer U, Ermler U, Shima S
    Crystal structure of FAD-independent methylene-tetrahydrofolate reductase from Mycobacterium hassiacum
    Proteins. 2023; 91(9): 1329-1340. https://doi.org/10.1002/prot.26504
    DORA PSI
  • Goebel L, Kirschner T, Koska S, Rai A, Janning P, Maffini S, et al.
    Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
    eLife. 2023; 12: e82184 (22 pp.). https://doi.org/10.7554/elife.82184
    DORA PSI
  • Grädler U, Schwarz D, Wegener A, Eichhorn T, Bandeiras TM, Freitas MC, et al.
    Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
    Journal of Biological Chemistry. 2023; 299(11): 105328 (14 pp.). https://doi.org/10.1016/j.jbc.2023.105328
    DORA PSI
  • Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren J-G, et al.
    Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide in clinical development
    Journal of Medicinal Chemistry. 2023; 66(14): 9401-9417. https://doi.org/10.1021/acs.jmedchem.3c00623
    DORA PSI
  • Heim C, Spring A-K, Kirchgäßner S, Schwarzer D, Hartmann MD
    Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron
    Biochemical and Biophysical Research Communications. 2023; 646: 30-35. https://doi.org/10.1016/j.bbrc.2023.01.051
    DORA PSI
  • Hellweg L, Edenhofer A, Barck L, Huppertz MC, Frei MS, Tarnawski M, et al.
    A general method for the development of multicolor biosensors with large dynamic ranges
    Nature Chemical Biology. 2023; 19: 1147-1157. https://doi.org/10.1038/s41589-023-01350-1
    DORA PSI
  • Hiemstra IH, Santegoets KCM, Janmaat ML, De Goeij BECG, Ten Hagen W, van Dooremalen S, et al.
    Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
    EBioMedicine. 2023; 93: 104663 (19 pp.). https://doi.org/10.1016/j.ebiom.2023.104663
    DORA PSI
  • Hommel U, Hurth K, Rondeau J-M, Vulpetti A, Ostermeier D, Boettcher A, et al.
    Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
    Nature Communications. 2023; 14(1): 5497 (13 pp.). https://doi.org/10.1038/s41467-023-41190-0
    DORA PSI
  • Imai Y, Suzuki R, Wakasugi D, Matsuda D, Tanaka-Yamamoto N, Ohki Y, et al.
    Structure-based lead optimization to improve potency and selectivity of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid series of heparanase-1 inhibitor
    Bioorganic and Medicinal Chemistry. 2023; 93: 117460 (15 pp.). https://doi.org/10.1016/j.bmc.2023.117460
    DORA PSI
  • Kalliokoski T, Kettunen H, Kumpulainen E, Kettunen E, Thieulin-Pardo G, Neumann L, et al.
    Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening
    Bioorganic and Medicinal Chemistry Letters. 2023; 94: 129450 (8 pp.). https://doi.org/10.1016/j.bmcl.2023.129450
    DORA PSI
  • Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, et al.
    Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
    Nature. 2023; 619(7968): 160-166. https://doi.org/10.1038/s41586-023-06123-3
    DORA PSI
  • Kompa J, Bruins J, Glogger M, Wilhelm J, Frei MS, Tarnawski M, et al.
    Exchangeable HaloTag ligands for super-resolution fluorescence microscopy
    Journal of the American Chemical Society. 2023; 145(5): 3075-3083. https://doi.org/10.1021/jacs.2c11969
    DORA PSI
  • Krasavin M, Adamchik M, Bubyrev A, Heim C, Maiwald S, Zhukovsky D, et al.
    Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines
    European Journal of Medicinal Chemistry. 2023; 246: 114990 (12 pp.). https://doi.org/10.1016/j.ejmech.2022.114990
    DORA PSI
  • Krieger J, Sorrell FJ, Wegener AA, Leuthner B, Machrouhi-Porcher F, Hecht M, et al.
    Systematic potency and property assessment of VHL ligands and implications on PROTAC design
    ChemMedChem. 2023; 18(8): e202200615 (11 pp.). https://doi.org/10.1002/cmdc.202200615
    DORA PSI
  • Kuhn B, Ritter M, Benz J, Kocer B, Sarie JC, Hochstrasser R, et al.
    Novel potent and highly selective DDR1 inhibitors from integrated lead finding
    Medicinal Chemistry Research. 2023; 32(7): 1400-1425. https://doi.org/10.1007/s00044-023-03066-2
    DORA PSI
  • Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, et al.
    Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279
    Journal of Medicinal Chemistry. 2023; 66: 10473-10496. https://doi.org/10.1021/acs.jmedchem.3c00600
    DORA PSI
  • Liu J, Chiang H-C, Xiong W, Laurent V, Griffiths SC, Dülfer J, et al.
    A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer
    Journal for ImmunoTherapy of Cancer. 2023; 11(6): e006720 (14 pp.). https://doi.org/10.1136/jitc-2023-006720
    DORA PSI
  • Martinelli P, Schaaf O, Mantoulidis A, Martin LJ, Fuchs JE, Bader G, et al.
    Discovery of a chemical probe to study implications of BPTF bromodomain inhibition in cellular and in vivo experiments
    ChemMedChem. 2023; 18(6): e202200686 (8 pp.). https://doi.org/10.1002/cmdc.202200686
    DORA PSI
  • Mauxion F, Basquin J, Ozgur S, Rame M, Albrecht J, Schäfer I, et al.
    The human CNOT1-CNOT10-CNOT11 complex forms a structural platform for protein-protein interactions
    Cell Reports. 2023; 42(1): 111902 (18 pp.). https://doi.org/10.1016/j.celrep.2022.111902
    DORA PSI
  • Mesrouze Y, Gubler H, Villard F, Boesch R, Ottl J, Kallen J, et al.
    Biochemical and structural characterization of a peptidic inhibitor of the YAP:TEAD interaction that binds to the α-Helix Pocket on TEAD
    ACS Chemical Biology. 2023; 18(3): 643-651. https://doi.org/10.1021/acschembio.2c00936
    DORA PSI
  • Mhaindarkar VP, Rasche R, Kümmel D, Rudolph MG, Klostermeier D
    Structure of reverse gyrase with a minimal latch that supports ATP-dependent positive supercoiling without specific interactions with the topoisomerase domain
    Acta Crystallographica Section D: Structural Biology. 2023; 79(6): 498-507. https://doi.org/10.1107/S2059798323002565
    DORA PSI
  • Miyagi H, Suzuki M, Yasunaga M, Asada H, Iwata S, Saito J-ichi
    Structural insight into an anti-BRIL Fab as a G-protein-coupled receptor crystallization chaperone
    Acta Crystallographica Section D: Structural Biology. 2023; 79(5): 435-441. https://doi.org/10.1107/S205979832300311X
    DORA PSI
  • Nain-Perez A, Nilsson O, Lulla A, Håversen L, Brear P, Liljenberg S, et al.
    Tuning liver pyruvate kinase activity up or down with a new class of allosteric modulators
    European Journal of Medicinal Chemistry. 2023; 250: 115177 (18 pp.). https://doi.org/10.1016/j.ejmech.2023.115177
    DORA PSI
  • Ohta A, Tanada M, Shinohara S, Morita Y, Nakano K, Yamagishi Y, et al.
    Validation of a new methodology to create oral drugs beyond the rule of 5 for intracellular tough targets
    Journal of the American Chemical Society. 2023; 145(44): 24035-24051. https://doi.org/10.1021/jacs.3c07145
    DORA PSI
  • O’Dea R, Kazi N, Hoffmann-Benito A, Zhao Z, Recknagel S, Wendrich K, et al.
    Molecular basis for ubiquitin/Fubi cross-reactivity in USP16 and USP36
    Nature Chemical Biology. 2023; 19(11): 1394-1405. https://doi.org/10.1038/s41589-023-01388-1
    DORA PSI
  • Roehrig S, Ackerstaff J, Jiménez Núñez E, Teller H, Ellerbrock P, Meier K, et al.
    Design and preclinical characterization program toward Asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders
    Journal of Medicinal Chemistry. 2023; 66(17): 12203-12224. https://doi.org/10.1021/acs.jmedchem.3c00795
    DORA PSI
  • Rutz S, Deneka D, Dittmann A, Sawicka M, Dutzler R
    Structure of a volume-regulated heteromeric LRRC8A/C channel
    Nature Structural and Molecular Biology. 2023; 30: 52-61. https://doi.org/10.1038/s41594-022-00899-0
    DORA PSI
  • Schmeing S, Amrahova G, Bigler K, Chang JY, Openy J, Pal S, et al.
    Rationally designed stapled peptides allosterically inhibit PTBP1-RNA-binding
    Chemical Science. 2023; 14(31): 8269-8278. https://doi.org/10.1039/d3sc00985h
    DORA PSI
  • Schröder M, Leiendecker M, Grädler U, Braun J, Blum A, Wanior M, et al.
    MSC-1186, a highly selective Pan-SRPK inhibitor based on an exceptionally decorated benzimidazole-pyrimidine core
    Journal of Medicinal Chemistry. 2023; 66(1): 837-854. https://doi.org/10.1021/acs.jmedchem.2c01705
    DORA PSI
  • Selim KA, Haffner M, Mantovani O, Albrecht R, Zhu H, Hagemann M, et al.
    Carbon signaling protein SbtB possesses atypical redox-regulated apyrase activity to facilitate regulation of bicarbonate transporter SbtA
    Proceedings of the National Academy of Sciences of the United States of America PNAS. 2023; 120(8): e2205882120 (11 pp.). https://doi.org/10.1073/pnas.2205882120
    DORA PSI
  • Sellner H, Chapeau E, Furet P, Voegtle M, Salem B, Le Douget M, et al.
    Optimization of a class of dihydrobenzofurane analogs toward orally efficacious YAP-TEAD protein-protein interaction inhibitors
    ChemMedChem. 2023; 18(11): e202300051 (23 pp.). https://doi.org/10.1002/cmdc.202300051
    DORA PSI
  • Sikandar A, Popoff A, Jumde RP, Mándi A, Kaur A, Elgaher WAM, et al.
    Revision of the absolute configurations of chelocardin and amidochelocardin
    Angewandte Chemie International Edition. 2023; 62(40): e202306437 (5 pp.). https://doi.org/10.1002/anie.202306437
    DORA PSI
  • Smith KML, Panepucci E, Kaminski JW, Aumonier S, Huang C-Y, Eris D, et al.
    SDU - software for high-throughput automated data collection at the Swiss Light Source
    Journal of Synchrotron Radiation. 2023; 30: 538-545. https://doi.org/10.1107/S1600577523002631
    DORA PSI
  • Spiller L, Manjula R, Leissing F, Basquin J, Bourilhon P, Sinitski D, et al.
    Plant MDL proteins synergize with the cytokine MIF at CXCR2 and CXCR4 receptors in human cells
    Science Signaling. 2023; 16(812): eadg2621 (18 pp.). https://doi.org/10.1126/scisignal.adg2621
    DORA PSI
  • Stegmann DP, Steuber J, Fritz G, Wojdyla JA, Sharpe ME
    Fast fragment and compound screening pipeline at the Swiss Light Source
    In: Methods in enzymology. sine loco: Elsevier; 2023:235-284. https://doi.org/10.1016/bs.mie.2023.08.005
    DORA PSI
  • Steinebach C, Bricelj A, Murgai A, Sosič I, Bischof L, Ng YLD, et al.
    Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs
    Journal of Medicinal Chemistry. 2023; 66(21): 14513-14543. https://doi.org/10.1021/acs.jmedchem.3c00851
    DORA PSI
  • Stephan P, Langley C, Winkler D, Basquin J, Caputi L, O'Connor SE, et al.
    Directed evolution of piperazic acid incorporation by a nonribosomal peptide synthetase**
    Angewandte Chemie International Edition. 2023; 62(35): e202304843 (6 pp.). https://doi.org/10.1002/anie.202304843
    DORA PSI
  • Thoma G, Markert C, Lueoend R, Miltz W, Spanka C, Bollbuck B, et al.
    Discovery of amino alcohols as highly potent, selective, and orally efficacious inhibitors of leukotriene A4 hydrolase
    European Journal of Medicinal Chemistry. 2023; 66: 16410-16425. https://doi.org/10.1021/acs.jmedchem.3c01866
    DORA PSI
  • Toure M, Johnson T, Li B, Schmidt R, Ma H, Neagu C, et al.
    Discovery of quinazoline HPK1 inhibitors with high cellular potency
    Bioorganic and Medicinal Chemistry. 2023; 92: 117423 (16 pp.). https://doi.org/10.1016/j.bmc.2023.117423
    DORA PSI
  • Valiente-Gabioud AA, Garteizgogeascoa Suñer I, Idziak A, Fabritius A, Basquin J, Angibaud J, et al.
    Fluorescent sensors for imaging of interstitial calcium
    Nature Communications. 2023; 14(1): 6220 (15 pp.). https://doi.org/10.1038/s41467-023-41928-w
    DORA PSI
  • Velcicky J, Janser P, Gommermann N, Brenneisen S, Ilic S, Vangrevelinghe E, et al.
    Discovery of potent, orally bioavailable, tricyclic NLRP3 inhibitors
    Journal of Medicinal Chemistry. 2023; 67: 1544-1562. https://doi.org/10.1021/acs.jmedchem.3c02098
    DORA PSI
  • Vulpetti A, Holzer P, Schmiedeberg N, Imbach-Weese P, Pissot-Soldermann C, Hollingworth GJ, et al.
    Discovery of new binders for DCAF1, an emerging ligase target in the targeted protein degradation field
    ACS Medicinal Chemistry Letters. 2023; 14(7): 949-954. https://doi.org/10.1021/acsmedchemlett.3c00104
    DORA PSI
  • Zhao Z, O’Dea R, Wendrich K, Kazi N, Gersch M
    Native semisynthesis of isopeptide-linked substrates for specificity analysis of deubiquitinases and Ubl proteases
    Journal of the American Chemical Society. 2023; 145(38): 20801-20812. https://doi.org/10.1021/jacs.3c04062
    DORA PSI
  • Altegoer F, Quax TEF, Weiland P, Nußbaum P, Giammarinaro PI, Patro M, et al.
    Structural insights into the mechanism of archaellar rotational switching
    Nature Communications. 2022; 13(1): 2857 (12 pp.). https://doi.org/10.1038/s41467-022-30358-9
    DORA PSI
  • Astashkin R, Kovalev K, Bukhdruker S, Vaganova S, Kuzmin A, Alekseev A, et al.
    Structural insights into light-driven anion pumping in cyanobacteria
    Nature Communications. 2022; 13(1): 6460 (13 pp.). https://doi.org/10.1038/s41467-022-34019-9
    DORA PSI
  • Aziz I, Kaltwasser S, Kayastha K, Khera R, Vonck J, Ermler U
    The molybdenum storage protein forms and deposits distinct polynuclear tungsten oxygen aggregates
    Journal of Inorganic Biochemistry. 2022; 234: 111904 (9 pp.). https://doi.org/10.1016/j.jinorgbio.2022.111904
    DORA PSI
  • Berneburg I, Rahlfs S, Becker K, Fritz-Wolf K
    Crystal structure of Leishmania donovani glucose 6-phosphate dehydrogenase reveals a unique N-terminal domain
    Communications Biology. 2022; 5(1): 1353 (14 pp.). https://doi.org/10.1038/s42003-022-04307-7
    DORA PSI
  • Beroza P, Crawford JJ, Ganichkin O, Gendelev L, Harris SF, Klein R, et al.
    Chemical space docking enables large-scale structure-based virtual screening to discover ROCK1 kinase inhibitors
    Nature Communications. 2022; 13(1): 6447 (10 pp.). https://doi.org/10.1038/s41467-022-33981-8
    DORA PSI
  • Botte M, Ni D, Schenck S, Zimmermann I, Chami M, Bocquet N, et al.
    Cryo-EM structures of a LptDE transporter in complex with Pro-macrobodies offer insight into lipopolysaccharide translocation
    Nature Communications. 2022; 13(1): 1826 (10 pp.). https://doi.org/10.1038/s41467-022-29459-2
    DORA PSI
  • Bröker J, Waterson AG, Smethurst C, Kessler D, Böttcher J, Mayer M, et al.
    Fragment optimization of reversible binding to the switch II pocket on KRAS leads to a potent, in vivo active KRASG12C inhibitor
    Journal of Medicinal Chemistry. 2022; 65(21): 14614-14629. https://doi.org/10.1021/acs.jmedchem.2c01120
    DORA PSI
  • Carvalho LAR, Ross B, Fehr L, Bolgi O, Wöhrle S, Lum KM, et al.
    Chemoproteomics-enabled identification of 4-Oxo-β-lactams as inhibitors of dipeptidyl peptidases 8 and 9
    Angewandte Chemie International Edition. 2022; 61(47): e202210498 (10 pp.). https://doi.org/10.1002/anie.202210498
    DORA PSI
  • Chakrabarti KS, Olsson S, Pratihar S, Giller K, Overkamp K, Lee KO, et al.
    A litmus test for classifying recognition mechanisms of transiently binding proteins
    Nature Communications. 2022; 13(1): 3792 (11 pp.). https://doi.org/10.1038/s41467-022-31374-5
    DORA PSI
  • Chrustowicz J, Sherpa D, Teyra J, Loke MS, Popowicz GM, Basquin J, et al.
    Multifaceted N-degron recognition and ubiquitylation by GID/CTLH E3 ligases
    Journal of Molecular Biology. 2022; 434(2): 167347 (22 pp.). https://doi.org/10.1016/j.jmb.2021.167347
    DORA PSI
  • Cisar JS, Pietsch C, DeRatt LG, Jacoby E, Kazmi F, Keohane C, et al.
    N-heterocyclic 3-pyridyl carboxamide inhibitors of DHODH for the treatment of acute myelogenous leukemia
    Journal of Medicinal Chemistry. 2022; 65(16): 11241-11256. https://doi.org/10.1021/acs.jmedchem.2c00788
    DORA PSI
  • Dahms SO, Schnapp G, Winter M, Büttner FH, Schlepütz M, Gnamm C, et al.
    Dichlorophenylpyridine-based molecules inhibit furin through an induced-fit mechanism
    ACS Chemical Biology. 2022; 17(4): 816-821. https://doi.org/10.1021/acschembio.2c00103
    DORA PSI
  • Davies C, Dötsch L, Ciulla MG, Hennes E, Yoshida K, Gasper R, et al.
    Identification of a novel pseudo‐natural product type IV IDO1 inhibitor chemotype
    Angewandte Chemie International Edition. 2022; 61(40): e202209374 (12 pp.). https://doi.org/10.1002/anie.202209374
    DORA PSI
  • Diaz E, Adhikary S, Tepper AWJW, Riley D, Ortiz-Meoz R, Krosky D, et al.
    Structure of human spermine oxidase in complex with a highly selective allosteric inhibitor
    Communications Biology. 2022; 5(1): 787 (14 pp.). https://doi.org/10.1038/s42003-022-03735-9
    DORA PSI
  • Dillenberger M, Rahlfs S, Becker K, Fritz-Wolf K
    Prominent role of cysteine residues C49 and C343 in regulating Plasmodium falciparum pyruvate kinase activity
    Structure. 2022; 30(10): 1452-1461.e3. https://doi.org/10.1016/j.str.2022.08.001
    DORA PSI
  • Fairhurst RA, Furet P, Imbach-Weese P, Stauffer F, Rueeger H, McCarthy C, et al.
    Identification of NVP-CLR457 as an orally bioavailable Non-CNS-Penetrant pan-class IA phosphoinositol-3-kinase inhibitor
    Journal of Medicinal Chemistry. 2022; 65(12): 8345-8379. https://doi.org/10.1021/acs.jmedchem.2c00267
    DORA PSI
  • Frei MS, Tarnawski M, Roberti MJ, Koch B, Hiblot J, Johnsson K
    Engineered HaloTag variants for fluorescence lifetime multiplexing
    Nature Methods. 2022; 19(1): 65-70. https://doi.org/10.1038/s41592-021-01341-x
    DORA PSI
  • Fritz-Wolf K, Bathke J, Rahlfs S, Becker K
    Crystal structure of plasmoredoxin, a redox-active protein unique for malaria parasites
    Current Research in Structural Biology. 2022; 4: 87-95. https://doi.org/10.1016/j.crstbi.2022.03.004
    DORA PSI
  • Furet P, Bordas V, Le Douget M, Salem B, Mesrouze Y, Imbach-Weese P, et al.
    The first class of small molecules potently disrupting the YAP-TEAD interaction by direct competition
    ChemMedChem. 2022; 17(19): e202200303 (14 pp.). https://doi.org/10.1002/cmdc.202200303
    DORA PSI
  • Gao L, Meiring JCM, Varady A, Ruider IE, Heise C, Wranik M, et al.
    In vivo photocontrol of microtubule dynamics and integrity, migration and mitosis, by the potent GFP-imaging-compatible photoswitchable reagents SBTubA4P and SBTub2M
    Journal of the American Chemical Society. 2022; 144(12): 5614-5628. https://doi.org/10.1021/jacs.2c01020
    DORA PSI
  • Gehrtz P, Marom S, Bührmann M, Hardick J, Kleinbölting S, Shraga A, et al.
    Optimization of covalent MKK7 inhibitors via crude nanomole-scale libraries
    Journal of Medicinal Chemistry. 2022; 65(15): 10341-10356. https://doi.org/10.1021/acs.jmedchem.1c02206
    DORA PSI
  • Goepfert A, Barske C, Lehmann S, Wirth E, Willemsen J, Gudjonsson JE, et al.
    IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling
    Cell Reports. 2022; 41(3): 111489 (19 pp.). https://doi.org/10.1016/j.celrep.2022.111489
    DORA PSI
  • Grabe T, Jeyakumar K, Niggenaber J, Schulz T, Koska S, Kleinbölting S, et al.
    Addressing the osimertinib resistance mutation EGFR-L858R/C797S with reversible aminopyrimidines
    ACS Medicinal Chemistry Letters. 2022; 14: 591-598. https://doi.org/10.1021/acsmedchemlett.2c00514
    DORA PSI
  • Grethe C, Schmidt M, Kipka G-M, O’Dea R, Gallant K, Janning P, et al.
    Structural basis for specific inhibition of the deubiquitinase UCHL1
    Nature Communications. 2022; 13(1): 5950 (17 pp.). https://doi.org/10.1038/s41467-022-33559-4
    DORA PSI
  • Heim C, Hartmann MD
    High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system
    Acta Crystallographica Section D: Structural Biology. 2022; 78: 290-298. https://doi.org/10.1107/S2059798322000092
    DORA PSI
  • Heim C, Spring AK, Kirchgäßner S, Schwarzer D, Hartmann MD
    Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon
    Biochemical and Biophysical Research Communications. 2022; 637: 66 (7 pp.)-72. https://doi.org/10.1016/j.bbrc.2022.11.001
    DORA PSI
  • Heimsch KC, Gertzen CGW, Schuh AK, Nietzel T, Rahlfs S, Przyborski JM, et al.
    Structure and function of redox-sensitive superfolder green fluorescent protein variant
    Antioxidants and Redox Signaling. 2022; 37(1-3): 1-18. https://doi.org/10.1089/ars.2021.0234
    DORA PSI
  • Hernández Lozada NJ, Hong B, Wood JC, Caputi L, Basquin J, Chuang L, et al.
    Biocatalytic routes to stereo-divergent iridoids
    Nature Communications. 2022; 13(1): 4718 (13 pp.). https://doi.org/10.1038/s41467-022-32414-w
    DORA PSI
  • Huang Y, Sendzik M, Zhang J, Gao Z, Sun Y, Wang L, et al.
    Discovery of the clinical candidate MAK683: an EED-directed, allosteric, and selective PRC2 inhibitor for the treatment of advanced malignancies
    Journal of Medicinal Chemistry. 2022; 65(7): 5317-5333. https://doi.org/10.1021/acs.jmedchem.1c02148
    DORA PSI
  • Huang C-Y, Aumonier S, Engilberge S, Eris D, Smith KML, Leonarski F, et al.
    Probing ligand binding of endothiapepsin by 'temperature-resolved' macromolecular crystallography
    Acta Crystallographica Section D: Structural Biology. 2022; 78: 964-974. https://doi.org/10.1107/S205979832200612X
    DORA PSI
  • Huyton T, Jaiswal M, Taxer W, Fischer M, Görlich D
    Crystal structures of FNIP/FGxxFN motif-containing leucine-rich repeat proteins
    Scientific Reports. 2022; 12(1): 16430 (12 pp.). https://doi.org/10.1038/s41598-022-20758-8
    DORA PSI
  • Iskhakova ZI, Zhuravleva DE, Heim C, Hartmann MD, Laykov AV, Forchhammer K, et al.
    PotN represents a novel energy-state sensing PII subfamily, occurring in firmicutes
    FEBS Journal. 2022; 289(17): 5305-5321. https://doi.org/10.1111/febs.16431
    DORA PSI
  • Kemble AM, Hornsperger B, Ruf I, Richter H, Benz J, Kuhn B, et al.
    A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature
    PLoS One. 2022; 17(9): e0268590 (24 pp.). https://doi.org/10.1371/journal.pone.0268590
    DORA PSI
  • Kofink C, Trainor N, Mair B, Wöhrle S, Wurm M, Mischerikow N, et al.
    A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
    Nature Communications. 2022; 13(1): 5969 (15 pp.). https://doi.org/10.1038/s41467-022-33430-6
    DORA PSI
  • Krasavin M, Bubyrev A, Kazantsev A, Heim C, Maiwald S, Zhukovsky D, et al.
    Replacing the phthalimide core in thalidomide with benzotriazole
    Journal of Enzyme Inhibition and Medicinal Chemistry. 2022; 37(1): 527-530. https://doi.org/10.1080/14756366.2021.2024525
    DORA PSI
  • Kubacka D, Kozarski M, Baranowski MR, Wojcik R, Panecka‐Hofman J, Strzelecka D, et al.
    Substrate‐based design of cytosolic nucleotidase IIIB inhibitors and structural insights into inhibition mechanism
    Pharmaceuticals. 2022; 15(5): 554 (27 pp.). https://doi.org/10.3390/ph15050554
    DORA PSI
  • Ladduwahetty T, Lee MR, Maillard MC, Cachope R, Todd D, Barnes M, et al.
    Identification of a potent, selective, and brain-penetrant Rho kinase inhibitor and its activity in a mouse model of Huntington's disease
    Journal of Medicinal Chemistry. 2022; 65(14): 9819-9845. https://doi.org/10.1021/acs.jmedchem.2c00474
    DORA PSI
  • Langley C, Tatsis E, Hong B, Nakamura Y, Paetz C, Stevenson CEM, et al.
    Expansion of the catalytic repertoire of alcohol dehydrogenases in plant metabolism
    Angewandte Chemie International Edition. 2022; 61(48): e202210934 (7 pp.). https://doi.org/10.1002/anie.202210934
    DORA PSI
  • Langlois CR, Beier V, Karayel O, Chrustowicz J, Sherpa D, Mann M, et al.
    A GID E3 ligase assembly ubiquitinates an Rsp5 E3 adaptor and regulates plasma membrane transporters
    EMBO Reports. 2022; 23(6): e53835 (17 pp.). https://doi.org/10.15252/embr.202153835
    DORA PSI
  • Langousis G, Sanchez J, Kempf G, Matthias P
    Expression and crystallization of HDAC6 tandem catalytic domains
    In: Krämer OH, ed. HDAC/HAT function assessment and inhibitor development. Methods and protocols. Methods in molecular biology. New York: Humana; 2022:467-480. https://doi.org/10.1007/978-1-0716-2788-4_30
    DORA PSI
  • Lategahn J, Tumbrink HL, Schultz-Fademrecht C, Heimsoeth A, Werr L, Niggenaber J, et al.
    Insight into targeting exon20 insertion mutations of the epidermal growth factor receptor with wild type-sparing inhibitors
    Journal of Medicinal Chemistry. 2022; 65(9): 6643-6655. https://doi.org/10.1021/acs.jmedchem.1c02080
    DORA PSI
  • Li D, Sloman DL, Achab A, Zhou H, McGowan MA, White C, et al.
    Oxetane promise delivered: discovery of long-acting IDO1 inhibitors suitable for Q3W oral or parenteral dosing
    Journal of Medicinal Chemistry. 2022; 65(8): 6001-6016. https://doi.org/10.1021/acs.jmedchem.1c01670
    DORA PSI
  • Lorthiois E, Gerspacher M, Beyer KS, Vaupel A, Leblanc C, Stringer R, et al.
    JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRASG12C for the treatment of solid tumors
    Journal of Medicinal Chemistry. 2022; 65(24): 16173-16203. https://doi.org/10.1021/acs.jmedchem.2c01438
    DORA PSI
  • Luebben AV, Bender D, Becker S, Crowther LM, Erven I, Hofmann K, et al.
    Cln5 represents a new type of cysteine-based S-depalmitoylase linked to neurodegeneration
    Science Advances. 2022; 8(15): eabj8633 (10 pp.). https://doi.org/10.1126/sciadv.abj8633
    DORA PSI
  • Mata G, Miles DH, Drew SL, Fournier J, Lawson KV, Mailyan AK, et al.
    Design, synthesis, and structure-activity relationship optimization of pyrazolopyrimidine amide inhibitors of phosphoinositide 3-kinase γ (PI3Kγ)
    Journal of Medicinal Chemistry. 2022; 65(2): 1418-1444. https://doi.org/10.1021/acs.jmedchem.1c01153
    DORA PSI
  • Milder FJ, Jongeneelen M, Ritschel T, Bouchier P, Bisschop IJM, de Man M, et al.
    Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions
    Proceedings of the National Academy of Sciences of the United States of America PNAS. 2022; 119(6): e2115379119 (8 pp.). https://doi.org/10.1073/pnas.2115379119
    DORA PSI
  • Moore KP, Schwaid AG, Tudor M, Park S, Beshore DC, Converso A, et al.
    A phenotypic screen identifies potent DPP9 inhibitors capable of killing HIV-1 infected cells
    ACS Chemical Biology. 2022; 17(9): 2595-2604. https://doi.org/10.1021/acschembio.2c00515
    DORA PSI
  • Obst-Sander U, Ricci A, Kuhn B, Friess T, Koldewey P, Kuglstatter A, et al.
    Discovery of novel allosteric EGFR L858R inhibitors for the treatment of non-small-cell lung cancer as a single agent or in combination with Osimertinib
    Journal of Medicinal Chemistry. 2022; 65(19): 13052-13073. https://doi.org/10.1021/acs.jmedchem.2c00893
    DORA PSI
  • Overbeck JH, Stelzig D, Fuchs AL, Wurm JP, Sprangers R
    Observation of conformational changes that underlie the catalytic cycle of Xrn2
    Nature Chemical Biology. 2022; 18: 1152-1160. https://doi.org/10.1038/s41589-022-01111-6
    DORA PSI
  • Pedrini B, Finke AD, Marsh M, Luporini P, Vallesi A, Alimenti C
    Crystal structure of the pheromone Er-13 from the ciliate Euplotes raikovi, with implications for a protein-protein association model in pheromone/receptor interactions
    Journal of Structural Biology. 2022; 214(1): 107812 (10 pp.). https://doi.org/10.1016/j.jsb.2021.107812
    DORA PSI
  • Rai A, Singh AK, Bleimling N, Posern G, Vetter IR, Goody RS
    Rep15 interacts with several Rab GTPases and has a distinct fold for a Rab effector
    Nature Communications. 2022; 13(1): 4262 (17 pp.). https://doi.org/10.1038/s41467-022-31831-1
    DORA PSI
  • Rigamonti N, Veitonmäki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, et al.
    A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression
    Cancer Immunology Research. 2022; 10(5): 626-640. https://doi.org/10.1158/2326-6066.CIR-21-0553
    DORA PSI
  • Romanov-Michailidis F, Hsiao C-C, Urner LM, Jerhaoui S, Surkyn M, Miller B, et al.
    Discovery of an oral, beyond-rule-of-five Mcl-1 protein-protein interaction modulator with the potential of treating hematological malignancies
    Journal of Medicinal Chemistry. 2022; 66(9): 6122-6148. https://doi.org/10.1021/acs.jmedchem.2c01953
    DORA PSI
  • Smith CR, Kulyk S, Ahmad MUD, Arkhipova V, Christensen JG, Gunn RJ, et al.
    Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits
    RSC Medicinal Chemistry. 2022; 13(12): 1549-1564. https://doi.org/10.1039/d2md00163b
    DORA PSI
  • Tosstorff A, Rudolph MG, Cole JC, Reutlinger M, Kramer C, Schaffhauser H, et al.
    A high quality, industrial data set for binding affinity prediction: performance comparison in different early drug discovery scenarios
    Journal of Computer-Aided Molecular Design. 2022; 36(10): 753-765. https://doi.org/10.1007/s10822-022-00478-x
    DORA PSI
  • Vollheyde K, Kühnel K, Lambrecht F, Kawelke S, Herrfurth C, Feussner I
    Crystal structure of the bifunctional wax synthase 1 from Acinetobacter baylyi suggests a conformational change upon substrate binding and formation of additional substrate binding sites
    ACS Catalysis. 2022; 12(15): 9753-9765. https://doi.org/10.1021/acscatal.2c01712
    DORA PSI
  • Vulpetti A, Lingel A, Dalvit C, Schiering N, Oberer L, Henry C, et al.
    Efficient Screening of Target-Specific Selected Compounds in Mixtures by 19F NMR Binding Assay with Predicted 19F NMR Chemical Shifts
    ChemMedChem. 2022; 17(13): e202200163 (9 pp.). https://doi.org/10.1002/cmdc.202200163
    DORA PSI
  • Weidenweber S, Schühle K, Lippert ML, Mock J, Seubert A, Demmer U, et al.
    Finis tolueni: a new type of thiolase with an integrated Zn-finger subunit catalyzes the final step of anaerobic toluene metabolism
    FEBS Journal. 2022; 289(18): 5599-5616. https://doi.org/10.1111/febs.16443
    DORA PSI
  • Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S, et al.
    BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
    Blood Cancer Journal. 2022; 12(7): 110 (10 pp.). https://doi.org/10.1038/s41408-022-00704-7
    DORA PSI
  • Weiss A, Lorthiois E, Barys L, Beyer KS, Bomio-Confaglia C, Burks H, et al.
    Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C
    Cancer Discovery. 2022; 12(6): 1500-1517. https://doi.org/10.1158/2159-8290.CD-22-0158
    DORA PSI
  • Wen X, Leisinger F, Leopold V, Seebeck FP
    Synthetic reagents for enzyme-catalyzed methylation
    Angewandte Chemie International Edition. 2022; 61: e202208746 (7 pp.). https://doi.org/10.1002/anie.202208746
    DORA PSI
  • Wilson A, Andreeva EA, Niziński S, Talbot L, Hartmann E, Schlichting I, et al.
    Structure-function-dynamics relationships in the peculiar Planktothrix PCC7805 OCP1: impact of his-tagging and carotenoid type
    Biochimica et Biophysica Acta: Bioenergetics. 2022; 1863(7): 148584 (24 pp.). https://doi.org/10.1016/j.bbabio.2022.148584
    DORA PSI
  • Xu G, Liu Z, Wang X, Lu T, Desjarlais RL, Thieu T, et al.
    Discovery of potent and orally bioavailable pyridine N-oxide-based factor XIa inhibitors through exploiting nonclassical interactions
    Journal of Medicinal Chemistry. 2022; 65(15): 10419-10440. https://doi.org/10.1021/acs.jmedchem.2c00442
    DORA PSI
  • de la Roche NM, Mühlethaler T, Di Martino RMC, Ortega JA, Gioia D, Roy B, et al.
    Novel fragment-derived colchicine-site binders as microtubule-destabilizing agents
    European Journal of Medicinal Chemistry. 2022; 241: 114614 (12 pp.). https://doi.org/10.1016/j.ejmech.2022.114614
    DORA PSI
  • Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, et al.
    Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
    Blood. 2021; 138(25): 2655 (15 pp.)-2669. https://doi.org/10.1182/blood.2020010477
    DORA PSI
  • Babu M, Favretto F, de Opakua AI, Rankovic M, Becker S, Zweckstetter M
    Proline/arginine dipeptide repeat polymers derail protein folding in amyotrophic lateral sclerosis
    Nature Communications. 2021; 12(1): 3396 (7 pp.). https://doi.org/10.1038/s41467-021-23691-y
    DORA PSI
  • Beale JH, Marsh ME
    Optimizing the growth of endothiapepsin crystals for serial crystallography experiments
    Journal of Visualized Experiments. 2021; 168: e61896 (30 pp.). https://doi.org/10.3791/61896
    DORA PSI
  • Benz J, Rufer AC, Huber S, Ehler A, Hug M, Topp A, et al.
    Novel β-Glucocerebrosidase activators that bind to a new pocket at a dimer interface and induce dimerization
    Angewandte Chemie International Edition. 2021; 60(10): 5436-5442. https://doi.org/10.1002/anie.202013890
    DORA PSI
  • Betschart C, Faller M, Zink F, Hemmig R, Blank J, Vangrevelinghe E, et al.
    Structure-based optimization of a fragment-like TLR8 binding screening hit to an in vivo efficacious TLR7/8 antagonist
    ACS Medicinal Chemistry Letters. 2021; 13(4): 658-664. https://doi.org/10.1021/acsmedchemlett.1c00696
    DORA PSI
  • Buchstaller H-P, Anlauf U, Dorsch D, Kögler S, Kuhn D, Lehmann M, et al.
    Optimization of a screening hit toward M2912, an oral tankyrase inhibitor with antitumor activity in colorectal cancer models
    Journal of Medicinal Chemistry. 2021; 64(14): 10371-10392. https://doi.org/10.1021/acs.jmedchem.1c00800
    DORA PSI
  • Centola M, van Pee K, Betz H, Yildiz Ö
    Crystal structures of phosphatidyl serine synthase PSS reveal the catalytic mechanism of CDP-DAG alcohol O-phosphatidyl transferases
    Nature Communications. 2021; 12(1): 6982 (13 pp.). https://doi.org/10.1038/s41467-021-27281-w
    DORA PSI
  • Chicano TM, Dietrich L, de Almeida NM, Akram M, Hartmann E, Leidreiter F, et al.
    Structural and functional characterization of the intracellular filament-forming nitrite oxidoreductase multiprotein complex
    Nature Microbiology. 2021; 6(9): 1129-1139. https://doi.org/10.1038/s41564-021-00934-8
    DORA PSI
  • Cretu C, Gee P, Liu X, Agrawal A, Nguyen TV, Ghosh AK, et al.
    Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors
    Nature Communications. 2021; 12(1): 4491 (15 pp.). https://doi.org/10.1038/s41467-021-24741-1
    DORA PSI
  • DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, et al.
    Identification of clinical candidate M2698, a dual p70S6K and akt inhibitor, for treatment of PAM pathway-altered cancers
    Journal of Medicinal Chemistry. 2021; 64(19): 14603-14619. https://doi.org/10.1021/acs.jmedchem.1c01087
    DORA PSI
  • Dekker C, Mattes H, Wright M, Boettcher A, Hinniger A, Hughes N, et al.
    Crystal structure of NLRP3 NACHT domain with an inhibitor defines mechanism of inflammasome inhibition
    Journal of Molecular Biology. 2021; 433(24): 167309 (11 pp.). https://doi.org/10.1016/j.jmb.2021.167309
    DORA PSI
  • Dietl A, Barends TRM
    Dynamics in an unusual acyl carrier protein from a ladderane lipid-synthesizing organism
    Proteins. 2021; 90(1): 73-82. https://doi.org/10.1002/prot.26187
    DORA PSI
  • Ebenhoch R, Bauer M, Reinert D, Kersting A, Huber S, Schmid A, et al.
    Biophysical and structural investigation of the regulation of human GTP cyclohydrolase I by its regulatory protein GFRP
    Journal of Structural Biology. 2021; 213(1): 107691 (10 pp.). https://doi.org/10.1016/j.jsb.2020.107691
    DORA PSI
  • Feldman HC, Ghosh R, Auyeung VC, Mueller JL, Kim JH, Potter ZE, et al.
    ATP-competitive partial antagonists of the IRE1α RNase segregate outputs of the UPR
    Nature Chemical Biology. 2021; 17(11): 1148-1156. https://doi.org/10.1038/s41589-021-00852-0
    DORA PSI
  • Fuchs ACD, Ammelburg M, Martin J, Schmitz RA, Hartmann MD, Lupas AN
    Archaeal Connectase is a specific and efficient protein ligase related to proteasome β subunits
    Proceedings of the National Academy of Sciences of the United States of America PNAS. 2021; 118(11): e2017871118 (9 pp.). https://doi.org/10.1073/pnas.2017871118
    DORA PSI
  • Fujimoto K, Yoshida S, Tadano G, Asada N, Fuchino K, Suzuki S, et al.
    Structure-based approaches to improving selectivity through utilizing explicit water molecules: discovery of selective β-secretase (BACE1) inhibitors over BACE2
    Journal of Medicinal Chemistry. 2021; 64(6): 3075-3085. https://doi.org/10.1021/acs.jmedchem.0c01858
    DORA PSI
  • Güttler T, Aksu M, Dickmanns A, Stegmann KM, Gregor K, Rees R, et al.
    Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies
    EMBO Journal. 2021; 40(19): e107985 (26 pp.). https://doi.org/10.15252/embj.2021107985
    DORA PSI
  • Hart P 't., Hommen P, Noisier A, Krzyzanowski A, Schüler D, Porfetye AT, et al.
    Structure based design of bicyclic Peptide inhibitors of RbAp48
    Angewandte Chemie International Edition. 2021; 60(4): 1813-1820. https://doi.org/10.1002/anie.202009749
    DORA PSI
  • He Y, Schild M, Grether U, Benz J, Leibrock L, Heer D, et al.
    Development of high brain-penetrant and reversible monoacylglycerol lipase PET tracers for neuroimaging
    Journal of Medicinal Chemistry. 2021; 65(3): 2191-2207. https://doi.org/10.1021/acs.jmedchem.1c01706
    DORA PSI
  • Herud-Sikimić O, Stiel AC, Kolb M, Shanmugaratnam S, Berendzen KW, Feldhaus C, et al.
    A biosensor for the direct visualization of auxin
    Nature. 2021; 592: 768-772. https://doi.org/10.1038/s41586-021-03425-2
    DORA PSI
  • Ibrahim A, Papin C, Mohideen-Abdul K, Gras SL, Stoll I, Bronner C, et al.
    MeCP2 is a microsatellite binding protein that protects CA repeats from nucleosome invasion
    Science. 2021; 372(6549): eabd5581 (14 pp.). https://doi.org/10.1126/science.abd5581
    DORA PSI
  • Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, et al.
    Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma
    European Journal of Medicinal Chemistry. 2021; 221: 113481 (16 pp.). https://doi.org/10.1016/j.ejmech.2021.113481
    DORA PSI
  • Johansson E, Wu X, Yu B, Yang Z, Cao Z, Wiberg C, et al.
    Insulin binding to the analytical antibody sandwich pair OXI‐005 and HUI‐018: epitope mapping and binding properties
    Protein Science. 2021; 30(2): 485-496. https://doi.org/10.1002/pro.4009
    DORA PSI
  • Kolos JM, Pomplun S, Jung S, Rieß B, Purder PL, Voll AM, et al.
    Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides
    Chemical Science. 2021; 12(44): 14758-14765. https://doi.org/10.1039/d1sc04638a
    DORA PSI
  • Konia E, Chatzicharalampous K, Drakonaki A, Muenke C, Ermler U, Tsiotis G, et al.
    Rational engineering of Luminiphilus syltensis (R)-selective amine transaminase for the acceptance of bulky substrates
    Chemical Communications. 2021; 57(96): 12948-12951. https://doi.org/10.1039/d1cc04664k
    DORA PSI
  • Kostrhon S, Prabu JR, Baek K, Horn-Ghetko D, von Gronau S, Klügel M, et al.
    CUL5-ARIH2 E3-E3 ubiquitin ligase structure reveals cullin-specific NEDD8 activation
    Nature Chemical Biology. 2021; 17: 1075-1083. https://doi.org/10.1038/s41589-021-00858-8
    DORA PSI
  • Krzyzanowski A, Gasper R, Adihou H, Hart P ’t, Waldmann H
    Biochemical Investigation of the Interaction of pICln, RioK1 and COPR5 with the PRMT5–MEP50 Complex
    ChemBioChem. 2021; 22(11): 1908-1914. https://doi.org/10.1002/cbic.202100079
    DORA PSI